| [1] Lawton J, McGrath J, Jones JS, et al. Treatment of coronary artery disease in an anomalous coronary artery by placement of an intracoronary stent. Cathet Cardiovasc Diagn. 1997;41(2): 185-188. [2] Yang JH, Choi SH, Song YB, et al. Long-term outcomes of drug-eluting stent implantation versus coronary artery bypass grafting for patients with coronary artery disease and chronic left ventricular systolic dysfunction. Am J Cardiol. 2013;112(5): 623-629. [3] Kong KL, Fong AYY, Mejin M, et al. PM222 Early Clinical Outcomes In Patients Electively Implanted With Everolimus And Non-Everolimus Drug Eluting Stents: Impact Of Platelet Function Testing Following Pretreatment With Aspirin And Clopidogrel. Global Heart. 2014;9(1, Supplement):e108. [4] Hayashi T, Kotani J, Ishibashi-Ueda H, et al. Thrombus-related focal in-stent restenosis after everolimus-eluting stent implantation. Heart Vessels. 2014;29(2):273-277. [5] Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008; 299(16):1903-1913. [6] Palmerini T, Kirtane AJ, Serruys PW, et al. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv. 2012;5(3): 357-364. [7] Hasskarl J. Everolimus. Recent Results Cancer Res. 2014;201: 373-392. [8] Martinet W, Verheye S, De Meyer GR. Everolimus-induced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy. Autophagy. 2007;3(3):241-244. [9] Lebwohl D, Anak O, Sahmoud T, et al. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Ann N Y Acad Sci. 2013;1291:14-32. [10] von Birgelen C, van der Heijden LC, Basalus MW, et al. Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2017;2(3):268-276. [11] Sotomi Y, Suwannasom P, Tenekecioglu E, et al. Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use. Expert Rev Cardiovasc Ther. 2015;13(10): 1127-1145. [12] Gatto P, Dumonteil N, Boudou N, et al. Incomplete stent apposition and very late stent thrombosis after everolimus eluting stent implantation and dual antiplatelet therapy interruption. A case of OCT guided therapy. Int J Cardiol. 2015;180:52-54. [13] Ahn JM, Park GM, Cho YR, et al. Comparison of Platinum Chromium Versus Cobalt Chromium Everolimus-eluting Stent in Real World Practice: Outcomes from the Multicenter Prospective IRIS-DES Registry. Am J Cardiol 2013;111(7, Supplement):2B. [14] Barbash IM, Minha S, Torguson R, et al. Long-term safety and efficacy of the everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice. J Invasive Cardiol. 2014;26(4):154-160. [15] Morino Y, Terashita D, Otake H, et al. Early vascular responses to everolimus-eluting cobalt-chromium stent in the culprit lesions of st-elevation myocardial infarction: results from a multicenter prospective optical coherence tomography study (MECHANISM-AMI 2-week follow-up study). Cardiovasc Interv Ther. 2018. doi: 10. 1007/s12928-017-0507-4. [16] Buszman PP, Michalak MJ, Pruski M, et al. Comparable vascular response of a new generation sirolimus eluting stents when compared to fluoropolymer everolimus eluting stents in the porcine coronary restenosis model. Cardiol J. 2016;23(6):657-666. [17] Calfon Press MA, Mallas G, Rosenthal A, et al. Everolimus-eluting stents stabilize plaque inflammation in vivo: assessment by intravascular fluorescence molecular imaging. Eur Heart J Cardiovasc Imaging. 2017;18(5):510-518. [18] Shibata Y, Yano H, Horinaka S, et al. Everolimus-eluting stent suppresses chronic inflammatory reaction compared with bare metal stent in off-label patients. Eur Heart J. 2013;34(Suppl 1): 4807-4817. [19] Karakulak UN, Yorgun H, ?ahiner L, et al. OP-008 Evaluation of Effectiveness and Safety of Everolimus Eluting Stent System (XIENCE V) in Patients with Atrial Fibrillation. Am J Cardiol. 2014; 113(7, Supplement):S3. [20] Aoki J, Kozuma K, Awata M, et al. Five-year clinical outcomes of everolimus-eluting stents from the post marketing study of CoCr-EES (XIENCE V/PROMUS) in Japan. Cardiovasc Interv Ther. 2018. doi: 10. 1007/s12928-018-0515-z[21] Konishi A, Iwasaki M, Shinke T, et al. Favorable early vessel healing after everolimus-eluting stent implantation: 3-, 6-, and 12-month follow-up of optical coherence tomography. J Cardiol. 2018;72(3):193-199. [22] Naito R, Miyauchi K, Konishi H, et al. Early definite stent thrombosis with everolimus-eluting stents. Clin Case Rep. 2015; 3(10):854-857. [23] Nakajima Y, Itoh T, Morino Y. Metal allergy to everolimus-eluting cobalt chromium stents confirmed by positive skin testing as a cause of recurrent multivessel in-stent restenosis. Catheter Cardiovasc Interv. 2016;87(4):E137-142. [24] Giudice P, Attisano T, Di Maio M, et al. Coronary vasomotion dysfunction after everolimus-eluting stent implantation. Interv Med Appl Sci. 2014;6(4):178-182. [25] Yano H, Horinaka S, Ishikawa M, et al. Early vascular responses after everolimus-eluting stent implantation assessed by serial observations of intracoronary optical coherence tomography. Heart Vessels. 2017;32(7):804-812. [26] Sabate M, Cequier A, Iñiguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION):1 year results of a randomised controlled trial. Lancet. 2012;380(9852):1482-1490. [27] Otsuka F, Vorpahl M, Nakano M, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation. 2014;129(2):211-223. [28] Chin-Quee SL, Hsu SH, Nguyen-Ehrenreich KL, et al. Endothelial cell recovery, acute thrombogenicity, and monocyte adhesion and activation on fluorinated copolymer and phosphorylcholine polymer stent coatings. Biomaterials. 2010;31(4):648-657. [29] Hiromasa T, Kuramitsu S, Shinozaki T, et al. Impact of total stent length after cobalt chromium everolimus-eluting stent implantation on 3-year clinical outcomes. Catheter Cardiovasc Interv. 2017; 89(2):207-216. [30] Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur Heart J. 2015;36(47):3320-3331. [31] Hoppmann P, Kufner S, Cassese S, et al. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry. Catheter Cardiovasc Interv. 2016; 87(5): 822-829. [32] Basavarajaiah S, Naganuma T, Latib A, et al. Extended follow-up following "full-metal jacket" percutaneous coronary interventions with drug-eluting stents. Catheter Cardiovasc Interv. 2014;84(7): 1042-1050. [33] Honari G, Ellis SG, Wilkoff BL, et al. Hypersensitivity reactions associated with endovascular devices. Contact Dermatitis. 2008; 59(1):7-22. [34] Hermiller JB, Krucoff MW, Kereiakes DJ, et al. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. JACC Cardiovasc Interv. 2016;9(2):138-147. [35] Zamiri P, Kuang Y, Sharma U, et al. The biocompatibility of rapidly degrading polymeric stents in porcine carotid arteries. Biomaterials. 2010;31(31):7847-7855. [36] Bae IH, Jeong MH, Lim KS, et al. Novel Polymer-Free Everolimus-Eluting Stent Fabricated using Femtosecond Laser Improves Re-endothelialization and Anti-inflammation. Sci Rep. 2018;8(1):7383. [37] Jeon H, Koo S, Reese WM, et al. Directing cell migration and organization via nanocrater-patterned cell-repellent interfaces. Nat Mater. 2015;14(9):918-923. [38] Sprimont P, Pierard S, Vanoverschelde JL, et al. Efficacy and safety of biodegradable polymer biolimus A9-eluting stent versus durable polymer everolimus-eluting stent in diabetic patients: a prospective non-randomized single-centre long-term comparison. Acta Cardiol. 2014;69(5):523-531. [39] Arroyo DA, Schukraft S, Kallinikou Z, et al. Multianalysis with optical coherence tomography and vasomotion in everolimus-eluting stents and everolimus-eluting biovascular scaffolds: the MOVES trial. Open Heart. 2018;5(1):e000624. [40] Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB):2-year outcomes and results from multiple imaging methods. Lancet. 2009;373(9667):897-910. [41] Ota H, Mahmoudi M, Torguson R, et al. Safety and efficacy of everolimus-eluting stents for bare-metal in-stent restenosis. Cardiovasc Revasc Med. 2015;16(3):151-155. [42] Vogt F, Blindt R, Hoffmann R, et al. TCT-824 Improved Safety And Efficacy Of A Novel Dual cRGD- And Everolimus-coated Coronary Stent Compared To Everolimus-eluting Stents In The Porcine Model. J Am Coll Cardiol 2013;62(18, Supplement 1):B249. [43] Stone GW, Teirstein PS, Meredith IT, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. J Am Coll Cardiol. 2011;57(16): 1700-1708. [44] Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv. 2007;69(1):128-131. [45] Sabaté M, Windecker S, Iñiguez A, et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J. 2016;37(3):229-240. [46] Choi HH, Kim JS, Yoon DH, et al. Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation: comparison with sirolimus-eluting stent using optical coherence tomography. Int J Cardiovasc Imaging. 2012;28(3):491-497. [47] 张娜娜,魏广和,张韶辉,等.西罗莫司与依维莫司药物洗脱支架治疗非ST段抬高型急性冠状动脉综合征的疗效比较[J].中国循环杂志, 2016,31(5):437-441.[48] Onuma Y, Miquel-Hebert K, Serruys PW, et al. Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial. EuroIntervention. 2013;8(9):1047-1051. [49] Claessen BE, Smits PC, Kereiakes DJ, et al. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. JACC Cardiovasc Interv. 2011;4(11):1209-1215. [50] 阮洁,蒋萍,苏晞.佐他莫司洗脱支架与依维莫司洗脱支架5年临床疗效比较[J].中国介入心脏病学杂志,2018,26(6):341-344.[51] Gu H, Hua K, Li W, et al. Safety and efficacy of everolimus-eluting stent versus zotarolimus-eluting stent: A meta-analysis of randomized controlled clinical trials and observational studies. Int J Cardiol. 2015;201:552-560. [52] Sprimont P, Pierard S, Vanoverschelde JL, et al. Efficacy and safety of biodegradable polymer biolimus A9-eluting stent versus durable polymer everolimus-eluting stent in diabetic patients: a prospective non-randomized single-centre long-term comparison. Acta Cardiol. 2014;69(5):523-531. [53] Smits PC, Hofma S, Togni M, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet. 2013;381(9867):651-660. [54] Connelly M. Cognitive behavioral therapy for treatment of pediatric chronic migraine. JAMA. 2013;310(24):2617-2618. [55] Stone GW, Sabik JF, Serruys PW, et al. Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. N Engl J Med. 2016;375(23):2223-2235. [56] Miura K, Tada T, Kuwayama A, et al. Stent Fracture and Peri-Stent Contrast Staining After Everolimus-Eluting Stent Implantation - 5-Year Outcomes. Circ J. 2017;81(10):1514-1521. [57] Kuramitsu S, Iwabuchi M, Domei T, et al. Response to letter regarding article, "incidence and clinical impact of stent fracture after everolimus-eluting stent implantation". Circ Cardiovasc Interv. 2013;6(1):e10. [58] Ji EY, Park GM, Kim DW, et al. Multiple Stent Fractures After Everolimus-Eluting Stent Implantation Causing Acute Myocardial Infarction: A Case Report. Medicine (Baltimore). 2016;95(6): e2704. [59] Park SJ, Ahn JM, Kim YH, et al. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med. 2015;372 (13):1204-1212. [60] Nomura T, Suzuki N, Takamura S, et al. Three-Year Clinical and Angiographic Outcomes After Everolimus-Eluting Stent Implantation in Patients With a History of Coronary Artery Bypass Grafting. Int Heart J. 2016;57(2):158-166. [61] Kadakia MB, Epps KC, Julien ME, et al. Early aneurysm formation after everolimus-eluting stent implantation. Circ Cardiovasc Interv. 2014;7(2):266-267. |
.jpg)
.jpg)